| Category | BioTech |
| Employees | |
| Founded | 2011 |
| TOTAL | $1.5M |
| VENTURE FUNDING TOTAL | $1.5M |
| Seed, 8/11 Stonehenge Capital Connecticut Innovations | $1.5M |
Thetis Pharmaceuticals is a development stage drug company focused on the treatment of Type 2 diabetes. Its initial candidate, TP101, has the credentials to deliver rigorous glucose and triglyceride control, along with unprecedented prospects for actually reducing the high incidence of cardiovascular events in diabetic patients. The company expects to open an IND and complete early clinical studies through Phase IIa trials within 3-4 years. Beyond TP101, Thetis is exploring other opportunities in the omega-3 and metformin arenas.
